German Merck, the world's oldest pharmaceutical, chemical and biological company, announced its intention to acquire American electronic components manufacturer Versum for 5 billion and 800 million euros. The boards of directors of both companies have already approved this deal. It must now be approved by the shareholders of Merck and the regulatory authorities. The transaction is expected to be completed in the second half of this year. Previously, Versum entered into a merger agreement with rival Entegris, which offered it $48 per share. However, Merck made a better offer –$53 a share, prompting Versum to break the deal with Entergris and pay it $140 million in compensation for the failure of the deal.
RBA buys semi-government bonds as coronavirus crushes state revenues20.03.2020
First round of QE sees Australia central bank buy $2.9 billion bonds18.03.2020
Airlines' cash drawers emptied, virus causes $157 billion loss from share values18.03.2020
German retailers' arms in the air as stores close